NCT03486431 - Clinical Trial References

Citation(s)

Alongi F, Arcangeli S, Filippi AR, Ricardi U, Scorsetti M
Review and uses of stereotactic body radiation therapy for oligometastases. Oncologist. 2012;17(8):1100-7. doi: 10.1634/theoncologist.2012-0092. Epub 2012 Jun 20.
Benedict SH, Yenice KM, Followill D, Galvin JM, Hinson W, Kavanagh B, Keall P, Lovelock M, Meeks S, Papiez L, Purdie T, Sadagopan R, Schell MC, Salter B, Schlesinger DJ, Shiu AS, Solberg T, Song DY, Stieber V, Timmerman R, Tome WA, Verellen D, Wang L, Yin FF
Stereotactic body radiation therapy: the report of AAPM Task Group 101. Med Phys. 2010 Aug;37(8):4078-101. doi: 10.1118/1.3438081. Erratum In: Med Phys. 2012 Jan;39(1):563. Dosage error in article text. Med Phys. 2023 Jun;50(6):3885.
Chevolet I, Speeckaert R, Schreuer M, Neyns B, Krysko O, Bachert C, Van Gele M, van Geel N, Brochez L
Clinical significance of plasmacytoid dendritic cells and myeloid-derived suppressor cells in melanoma. J Transl Med. 2015 Jan 16;13:9. doi: 10.1186/s12967-014-0376-x.
Corbin KS, Hellman S, Weichselbaum RR
Extracranial oligometastases: a subset of metastases curable with stereotactic radiotherapy. J Clin Oncol. 2013 Apr 10;31(11):1384-90. doi: 10.1200/JCO.2012.45.9651. Epub 2013 Mar 4. No abstract available.
de Jager W, Bourcier K, Rijkers GT, Prakken BJ, Seyfert-Margolis V
Prerequisites for cytokine measurements in clinical trials with multiplex immunoassays. BMC Immunol. 2009 Sep 28;10:52. doi: 10.1186/1471-2172-10-52.
de la Cruz-Merino L, Illescas-Vacas A, Grueso-Lopez A, Barco-Sanchez A, Miguez-Sanchez C; Cancer Immunotherapies Spanish Group (GETICA)
Radiation for Awakening the Dormant Immune System, a Promising Challenge to be Explored. Front Immunol. 2014 Mar 14;5:102. doi: 10.3389/fimmu.2014.00102. eCollection 2014.
Dewan MZ, Galloway AE, Kawashima N, Dewyngaert JK, Babb JS, Formenti SC, Demaria S
Fractionated but not single-dose radiotherapy induces an immune-mediated abscopal effect when combined with anti-CTLA-4 antibody. Clin Cancer Res. 2009 Sep 1;15(17):5379-88. doi: 10.1158/1078-0432.CCR-09-0265. Epub 2009 Aug 25.
Li J, Dittmar RL, Xia S, Zhang H, Du M, Huang CC, Druliner BR, Boardman L, Wang L
Cell-free DNA copy number variations in plasma from colorectal cancer patients. Mol Oncol. 2017 Aug;11(8):1099-1111. doi: 10.1002/1878-0261.12077. Epub 2017 Jun 6.
Martin OA, Anderson RL, Russell PA, Cox RA, Ivashkevich A, Swierczak A, Doherty JP, Jacobs DH, Smith J, Siva S, Daly PE, Ball DL, Martin RF, MacManus MP
Mobilization of viable tumor cells into the circulation during radiation therapy. Int J Radiat Oncol Biol Phys. 2014 Feb 1;88(2):395-403. doi: 10.1016/j.ijrobp.2013.10.033. Epub 2013 Dec 5.
Owen D, Laack NN, Mayo CS, Garces YI, Park SS, Bauer HJ, Nelson K, Miller RW, Brown PD, Olivier KR
Outcomes and toxicities of stereotactic body radiation therapy for non-spine bone oligometastases. Pract Radiat Oncol. 2014 Mar-Apr;4(2):e143-e149. doi: 10.1016/j.prro.2013.05.006. Epub 2013 Jun 29.
Palma DA, Haasbeek CJ, Rodrigues GB, Dahele M, Lock M, Yaremko B, Olson R, Liu M, Panarotto J, Griffioen GH, Gaede S, Slotman B, Senan S
Stereotactic ablative radiotherapy for comprehensive treatment of oligometastatic tumors (SABR-COMET): study protocol for a randomized phase II trial. BMC Cancer. 2012 Jul 23;12:305. doi: 10.1186/1471-2407-12-305.
Tree AC, Khoo VS, Eeles RA, Ahmed M, Dearnaley DP, Hawkins MA, Huddart RA, Nutting CM, Ostler PJ, van As NJ
Stereotactic body radiotherapy for oligometastases. Lancet Oncol. 2013 Jan;14(1):e28-37. doi: 10.1016/S1470-2045(12)70510-7.
Vanpouille-Box C, Alard A, Aryankalayil MJ, Sarfraz Y, Diamond JM, Schneider RJ, Inghirami G, Coleman CN, Formenti SC, Demaria S
DNA exonuclease Trex1 regulates radiotherapy-induced tumour immunogenicity. Nat Commun. 2017 Jun 9;8:15618. doi: 10.1038/ncomms15618.

A Phase I Dose-escalation Trial of Stereotactic Ablative Body Radiotherapy (SABR) for Non-spine Bone & Lymph Node Oligometastates

Details for clinical trial NCT03486431

Clinical trial NCT03486431 - References